News stories about Myovant Sciences (NASDAQ:MYOV) have trended somewhat negative on Sunday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Myovant Sciences earned a coverage optimism score of 0.00 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.7770266054011 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Separately, Zacks Investment Research cut Myovant Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Myovant Sciences has a consensus rating of “Buy” and an average target price of $18.20.

Myovant Sciences (MYOV) traded up 5.69% during trading on Friday, reaching $10.59. The company had a trading volume of 20,888 shares. Myovant Sciences has a one year low of $10.01 and a one year high of $15.50. The company has a 50-day moving average price of $11.35 and a 200 day moving average price of $11.80. The company’s market capitalization is $638.37 million.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/13/myovant-sciences-nasdaqmyov-given-daily-media-impact-score-of-0-00.html.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.